Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Accupril Patent Victory Could Lead To Influx Of Generics In 2005

Executive Summary

Accupril generics could enter the market as early as 2005 despite a court ruling finding a Pfizer quinapril patent to be valid
Advertisement

Related Content

Pfizer Obtains Preliminary Injunction Against Teva/Ranbaxy Accupril Generic
Pfizer Obtains Preliminary Injunction Against Teva/Ranbaxy Accupril Generic
Teva/Ranbaxy launch Accupril generic
Pfizer’s “Swift Response” To Neurontin Generics Gives Greenstone 23% Share
Pfizer Accupril “Branded Generic” Plans Challenged By Teva
Pfizer Urges FDA To Prohibit Generic Exclusivity Transfer For Gabapentin
Zoloft Patent Dispute: FTC Sides With Teva On Declaratory Judgment Rights
Mutual’s Accupril Declaratory Judgment Case Versus Pfizer Thrown Out
Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm
Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm

Topics

Advertisement
UsernamePublicRestriction

Register

PS044297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel